CYP2C9*2 and CYP2C9*3 allele variants of CYP2C9 cytochrome gene in St. Petersburg population, and their clinical role in warfarin anticoagulant therapy
| Autor: | O. V. Sirotkina, A. S. Ulitina, A. E. Taraskina, M. I. Kadinskaya, T. V. Vavilova, S. N. Pchelina, E. I. Shwartz |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2004 |
| Předmět: | |
| Zdroj: | Российский кардиологический журнал, Vol 0, Iss 6, Pp 47-50 (2004) |
| Druh dokumentu: | article |
| ISSN: | 1560-4071 2618-7620 |
| Popis: | One of the leading anticoagulants in Russia is warfarin. Its pharmacokinetics is determined by structural polymorphisms of CYP2C9 cytochrome gene, metabolizing warfarin. In the present study, the authors analyzed: 1) prevalence of two allele variants of this gene; 2) patients' individual reaction to warfarin, according to their CYP2C9 genotype. It was demonstrated that: 1) prevalence of CYP2C9 gene allele variants in St. Petersburg population was 82,66% (CYP2C9*1), 11,11% (CYP2C9*2), and 6,32% (CYP2C9*3); 2) individuals with CYP2C9*2 and CYP2C9*3 alleles reached therapeutic hypocoagulation faster, and required significantly lower weekly doses of the medication. Routine identification of CYP2C9*2 and CYP2C9*3 alleles is recommended to all patients administered warfarin. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|